1. Simha V. Management of hypertriglyceridemia. BMJ. Published online 2020:m3109. doi:10.1136/bmj.m3109
2. Toth PP, Shah PK, Lepor NE. Targeting hypertriglyceridemia to mitigate cardiovascular risk: A Review. American Journal of Preventive Cardiology. 2020;3:100086. doi:10.1016/j.ajpc.2020.100086
3. Arca M, Veronesi C, D’Erasmo L, et al. Association of hypertriglyceridemia with all‐cause mortality and atherosclerotic cardiovascular events in a low‐risk Italian population: The tg‐real retrospective cohort analysis. Journal of the American Heart Association. 2020;9(19). doi:10.1161/jaha.119.015801
4. Marston NA, Giugliano RP, Im K, et al. Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes. Circulation. 2019;140(16):1308-1317. doi:10.1161/circulationaha.119.041998
5. Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, Campbell SE, Oshima R, Amarenco P, Blom DJ, Brinton EA, Eckel RH, Elam MB, Felicio JS, Ginsberg HN, Goudev A, Ishibashi S, Joseph J, Kodama T, Koenig W, Leiter LA, Lorenzatti AJ, Mankovsky B, Marx N, Nordestgaard BG, Páll D, Ray KK, Santos RD, Soran H, Susekov A, Tendera M, Yokote K, Paynter NP, Buring JE, Libby P, Ridker PM; PROMINENT Investigators. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. N Engl J Med. 2022 Nov 24;387(21):1923-1934.
6. Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA. 2020;324(22):2268-2280. doi:10.1001/jama.2020.22258
7. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380(1):11-22. doi:10.1056/NEJMoa1812792
Facebook 
Masuk dengan Email
